Novartis Ag (NVS) Net Cash Flow Growth (1y) (2010 - 2026)
Novartis Ag (NVS) Net Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 93.66% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -323.06% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 248.11% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 195.58% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -0.70% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 349.49% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -55.11% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -517.34% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 78.10% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -99.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 195.58% |
| Dec 31, 2025 | 60.53% |
| Sep 30, 2025 | -13.76% |
| Jun 30, 2025 | 48.30% |
| Mar 31, 2025 | 136.71% |
| Dec 31, 2024 | -974.60% |
| Jun 30, 2024 | -33.22% |
| Mar 31, 2024 | -435.12% |
| Jun 30, 2023 | 88.70% |
| Jun 30, 2022 | -869.09% |
| Dec 31, 2021 | 249.84% |
| Sep 30, 2021 | -166.06% |
| Jun 30, 2021 | -3.01% |
| Dec 31, 2020 | -510.42% |
| Jun 30, 2020 | 123.97% |
| Dec 31, 2019 | 119.05% |
| Jun 30, 2019 | -91.46% |
| Dec 31, 2018 | -350.00% |
| Sep 30, 2018 | -29.34% |
| Jun 30, 2018 | 2,513.55% |